Posted by Michael Wonder on 12 Jan 2021
Acrux receives FDA approval for its generic testosterone topical solution
12 January 2021 - Acrux is pleased to announce that the US FDA has approved its generic product based on Perrigo’s testosterone topical solution, 30 mg/1.5 mL.
In August 2018, Acrux submitted an abbreviated new drug application to seek approval from the FDA to market a generic product equivalent to Perrigo’s testosterone topical solution, 30 mg/1.5 mL.
The FDA has notified Acrux that the submission has now been approved and that Acrux can manufacture and market the generic drug.
